The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2

Cancer biomarkers that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer (BC). The prevalence, clinicopathological and prognostic significance of PRPF38B expression in a consecutive series of 1650 patients with primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Fatah, Tarek M.A, Rees, Robert C, Pockley, A. Graham, Moseley, Paul, Ball, Graham R, Chan, Stephen Y.T, Ellis, Ian O, Miles, Amanda K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762507/
https://www.ncbi.nlm.nih.gov/pubmed/29348822
http://dx.doi.org/10.18632/oncotarget.22496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762507/
https://www.ncbi.nlm.nih.gov/pubmed/29348822
http://dx.doi.org/10.18632/oncotarget.22496

Ejemplares similares